Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2014

Open Access 01-12-2014 | Original research

Test-retest variability of adenosine A2A binding in the human brain with 11C-TMSX and PET

Authors: Mika Naganawa, Masahiro Mishina, Muneyuki Sakata, Keiichi Oda, Mikio Hiura, Kenji Ishii, Kiichi Ishiwata

Published in: EJNMMI Research | Issue 1/2014

Login to get access

Abstract

Background

The goal of the present study was to evaluate the reproducibility of cerebral adenosine A2A receptor (A2AR) quantification using 11C-TMSX and PET in a test-retest study.

Methods

Five healthy volunteers were studied twice. The test-retest variability was assessed for distribution volume (VT) and binding potential relative to non-displaceable uptake (BPND) based on either metabolite-corrected arterial blood sampling or a reference region. The cerebral cortex and centrum semiovale were used as candidate reference regions.

Results

Test-retest variability of VT was good in all regions (6% to 13%). In the putamen, BPND using the centrum semiovale displayed a lower test-retest variability (3%) than that of BPND using the cerebral cortex as a reference region (5%). The noninvasive method showed a higher or similar level of test-retest reproducibility compared to the invasive method.

Conclusions

Binding reproducibility is sufficient to use 11C-TMSX as a tool to measure the change in A2AR in the human brain.
Appendix
Available only for authorised users
Literature
1.
Ishiwata K, Noguchi J, Wakabayashi S, Shimada J, Ogi N, Nariai T, Tanaka A, Endo K, Suzuki F, Senda M: 11C-labeled KF18446: a potential central nervous system adenosine A2a receptor ligand. J Nucl Med 2000, 41: 345–354.PubMed
2.
Hirani E, Gillies J, Karasawa A, Shimada J, Kase H, Opacka-Juffry J, Osman S, Luthra SK, Hume SP, Brooks DJ: Evaluation of [4- O - methyl -11C]KW-6002 as a potential PET ligand for mapping central adenosine A2A receptors in rats. Synapse 2001, 42: 164–176. 10.1002/syn.1110CrossRefPubMed
3.
Brooks DJ, Doder M, Osman S, Luthra SK, Hirani E, Hume S, Kase H, Kilborn J, Martindill S, Mori A: Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain. Synapse 2008, 62: 671–681. 10.1002/syn.20539CrossRefPubMed
4.
Ishiwata K, Kawamura K, Kimura Y, Oda K, Ishii K: Potential of an adenosine A2A receptor antagonist [11C]TMSX for myocardial imaging by positron emission tomography: a first human study. Ann Nucl Med 2003, 17: 457–462. 10.1007/BF03006434CrossRefPubMed
5.
Ishiwata K, Mishina M, Kimura Y, Oda K, Sasaki T, Ishii K: First visualization of adenosine A2A receptors in the human brain by positron emission tomography with [11C]TMSX. Synapse 2005, 55: 133–136. 10.1002/syn.20099CrossRefPubMed
6.
Mishina M, Ishiwata K, Kimura Y, Naganawa M, Oda K, Kobayashi S, Katayama Y, Ishii K: Evaluation of distribution of adenosine A2A receptors in normal human brain measured with [11C]TMSX PET. Synapse 2007, 61: 778–784. 10.1002/syn.20423CrossRefPubMed
7.
Naganawa M, Kimura Y, Mishina M, Manabe Y, Chihara K, Oda K, Ishii K, Ishiwata K: Quantification of adenosine A2A receptors in the human brain using [11C]TMSX and positron emission tomography. Eur J Nucl Med Mol Imaging 2007, 34: 679–687. 10.1007/s00259-006-0294-0CrossRefPubMed
8.
Mishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M, Hashimoto M, Ishibashi K, Oda K, Sakata M, Hamamoto M, Kobayashi S, Katayama Y, Ishii K: Adenosine A2Areceptors measured with [11C]TMSX PET in the striata of Parkinson's disease patients. PLoS One 2011, 6: e17338.
9.
Mishina M, Kimura Y, Naganawa M, Ishii K, Oda K, Sakata M, Toyohara J, Kobayashi S, Katayama Y, Ishiwata K: Differential effects of age on human striatal adenosine A1 and A2A receptors. Synapse 2012, 66: 832–839. 10.1002/syn.21573CrossRefPubMed
10.
Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, Galli-Kienle M, Fazio F: In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. Eur J Nucl Med Mol Imaging 2005, 32: 405–413. 10.1007/s00259-004-1688-5CrossRefPubMed
11.
Mihara T, Noda A, Arai H, Mihara K, Iwashita A, Murakami Y, Matsuya T, Miyoshi S, Nishimura S, Matsuoka N: Brain adenosine A2A receptor occupancy by a novel A1/A2A receptor antagonist, ASP5854, in rhesus monkeys: relationship to anticataleptic effect. J Nucl Med 2008, 49: 1183–1188. 10.2967/jnumed.108.051474CrossRefPubMed
12.
Ishiwata K, Wang WF, Kimura Y, Kawamura K, Ishii K: Preclinical studies on [11C]TMSX for mapping adenosine A2A receptors by positron emission tomography. Ann Nucl Med 2003, 17: 205–211. 10.1007/BF02990023CrossRefPubMed
13.
Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, Ishii K, Orihara H, Fukuda H, Satoh T, Kitamura K, Tanaka K, Takahashi S: Performance evaluation of a large axial field-of-view PET scanner: SET-2400 W. Ann Nucl Med 1997, 11: 307–313. 10.1007/BF03165298CrossRefPubMed
14.
Mishina M, Senda M, Kimura Y, Toyama H, Ishiwata K, Ohyama M, Nariai T, Ishii K, Oda K, Sasaki T, Kitamura S, Katayama Y: Intrasubject correlation between static scan and distribution volume images for [11C]flumazenil PET. Ann Nucl Med 2000, 14: 193–198. 10.1007/BF02987859CrossRefPubMed
15.
Svenningsson P, Hall H, Sedvall G, Fredholm BB: Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse 1997, 27: 322–335. 10.1002/(SICI)1098-2396(199712)27:4<322::AID-SYN6>3.0.CO;2-ECrossRefPubMed
16.
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE: Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007, 27: 1533–1539. 10.1038/sj.jcbfm.9600493CrossRefPubMed
17.
Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ, Christman DR: Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990, 10: 740–747. 10.1038/jcbfm.1990.127CrossRefPubMed
18.
Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL: Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996, 16: 834–840. 10.1097/00004647-199609000-00008CrossRefPubMed
19.
Shrout PE, Fleiss JL: Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979, 86: 420–428. 10.1037/0033-2909.86.2.420CrossRefPubMed
20.
Ogden RT, Ojha A, Erlandsson K, Oquendo MA, Mann JJ, Parsey RV: In vivo quantification of serotonin transporters using [11C]DASB and positron emission tomography in humans: modeling considerations. J Cereb Blood Flow Metab 2007, 27: 205–217. 10.1038/sj.jcbfm.9600329PubMedCentralCrossRefPubMed
21.
Frankle WG, Slifstein M, Gunn RN, Huang Y, Hwang DR, Darr EA, Narendran R, Abi-Dargham A, Laruelle M: Estimation of serotonin transporter parameters with 11C-DASB in healthy humans: reproducibility and comparison of methods. J Nucl Med 2006, 47: 815–826.PubMed
22.
Faul F, Erdfelder E, Lang AG, Buchner A: G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007, 39: 175–191. 10.3758/BF03193146CrossRefPubMed
23.
Rissanen E, Virta JR, Paavilainen T, Tuisku J, Helin S, Luoto P, Parkkola R, Rinne JO, Airas L: Adenosine A2A receptors in secondary progressive multiple sclerosis: a [11C]TMSX brain PET study. J Cereb Blood Flow Metab 2013, 33: 1394–1401. 10.1038/jcbfm.2013.85PubMedCentralCrossRefPubMed
24.
Matusch A, Meyer PT, Bier D, Holschbach MH, Woitalla D, Elmenhorst D, Winz OH, Zilles K, Bauer A: Metabolism of the A1 adenosine receptor PET ligand [18 F]CPFPX by CYP1A2: implications for bolus/infusion PET studies. Nucl Med Biol 2006, 33: 891–898. 10.1016/j.nucmedbio.2006.07.006CrossRefPubMed
25.
Narendran R, Mason NS, May MA, Chen CM, Kendro S, Ridler K, Rabiner EA, Laruelle M, Mathis CA, Frankle WG: Positron emission tomography imaging of dopamine D2/3 receptors in the human cortex with [11C]FLB 457: reproducibility studies. Synapse 2011, 65: 35–40. 10.1002/syn.20813PubMedCentralCrossRefPubMed
26.
Elmenhorst D, Meyer PT, Matusch A, Winz OH, Zilles K, Bauer A: Test-retest stability of cerebral A1 adenosine receptor quantification using [18 F]CPFPX and PET. Eur J Nucl Med Mol Imaging 2007, 34: 1061–1070. 10.1007/s00259-006-0309-xCrossRefPubMed
27.
Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN: Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 2010, 30: 46–50. 10.1038/jcbfm.2009.190PubMedCentralCrossRefPubMed
28.
Gunn RN, Murthy V, Catafau AM, Searle G, Bullich S, Slifstein M, Ouellet D, Zamuner S, Herance R, Salinas C, Pardo-Lozano R, Rabiner EA, Farre M, Laruelle M: Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1. Synapse 2011, 65: 1319–1332. 10.1002/syn.20966CrossRefPubMed
29.
Elmenhorst D, Meyer PT, Matusch A, Winz OH, Bauer A: Caffeine occupancy of human cerebral A1 adenosine receptors: in vivo quantification with 18 F-CPFPX and PET. J Nucl Med 2012, 53: 1723–1729. 10.2967/jnumed.112.105114CrossRefPubMed
30.
Lindstrom K, Ongini E, Fredholm BB: The selective adenosine A2A receptor antagonist SCH 58261 discriminates between two different binding sites for [3H]-CGS 21680 in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 1996, 354: 539–541. 10.1007/BF00168448CrossRefPubMed
31.
Gallezot JD, Weinzimmer D, Nabulsi N, Lin SF, Fowles K, Sandiego C, McCarthy TJ, Maguire RP, Carson RE, Ding YS: Evaluation of [11C]MRB for assessment of occupancy of norepinephrine transporters: studies with atomoxetine in non-human primates. Neuroimage 2011, 56: 268–279. 10.1016/j.neuroimage.2010.09.040PubMedCentralCrossRefPubMed
32.
Tavares AA, Batis JC, Papin C, Jennings D, Alagille D, Russell DS, Vala C, Lee H, Baldwin RM, Zubal IG, Marek KL, Seibyl JP, Barret O, Tamagnan GD: Kinetic modeling, test-retest, and dosimetry of 123I-MNI-420 in humans. J Nucl Med 2013, 54: 1760–1767. 10.2967/jnumed.113.119933CrossRefPubMed
33.
Joshi AD, Sanabria-Bohorquez SM, Bormans G, Koole M, De Hoon J, Van Hecken A, Depre M, De Lepeleire I, Van Laere K, Sur C, Hamill TG: Characterization of the novel GlyT1 PET tracer [18 F]MK-6577 in humans. Synapse 2015, 69: 33–40. 10.1002/syn.21782CrossRefPubMed
Metadata
Title
Test-retest variability of adenosine A2A binding in the human brain with 11C-TMSX and PET
Authors
Mika Naganawa
Masahiro Mishina
Muneyuki Sakata
Keiichi Oda
Mikio Hiura
Kenji Ishii
Kiichi Ishiwata
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2014
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-014-0076-9

Other articles of this Issue 1/2014

EJNMMI Research 1/2014 Go to the issue

Original research

Effects on the FDG distribution by a high uptake of brown adipose tissue at PET examination

Original research

Study of inter- and intra-observer reproducibility in the interpretation of [18F]choline PET/CT examinations in patients suffering from biochemically recurrent prostate cancer following curative treatment

Original research

An evaluation of the brain distribution of [11C]GSK1034702, a muscarinic-1 (M1) positive allosteric modulator in the living human brain using positron emission tomography

Original research

Multiparametric magnetic resonance in the assessment of the gender differences in a high-grade glioma rat model

Original research

Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors

Original research

In vivo bioluminescence imaging for viable human neural stem cells incorporated within in situ gelatin hydrogels